-
EdU Imaging for TRIB3–Sunitinib Response
2026-09-19
TRIB3 knockdown has emerged as a potential strategy for increasing sunitinib sensitivity in clear cell renal cell carcinoma by engaging ferroptosis-related biology. This article explains how EdU-based DNA synthesis measurement can strengthen that mechanistic story, distinguish cell-cycle suppression from cell death, and support translational workflows using microscopy and flow cytometry.
-
Liraglutide and the Brain–Kidney AVP Axis
2026-09-19
Greenwood and colleagues combine a human before-and-after study with rat pituitary proteomics, phosphoproteomics, a functional AVP luciferase assay, and renal analysis to investigate how liraglutide influences fluid homeostasis. The findings connect reduced circulating vasopressin with sex- and time-dependent synaptic phosphorylation and downstream aquaporin 2 regulation, while also defining important limits for causal interpretation.
-
Entinostat (MS-275): From Mechanism to Translation
2026-09-18
Entinostat offers a selective HDAC1 and HDAC3-centered strategy for connecting chromatin biology with measurable cancer phenotypes. This translational framework integrates target engagement, time-resolved viability analysis, retinoblastoma treatment research, and clinical development considerations.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-09-18
Shiota et al. developed a dCas9-based functional screen that identified structurally diverse HDAC inhibitors as repressors of NUT transcriptional activity in NUT carcinoma. The study connects HDAC inhibition with depletion of BRD4-NUT from oncogenic megadomains, transcriptional reprogramming, tumor-cell differentiation, and improved xenograft responses when combined with bromodomain inhibition.
-
Tetrandrine Workflows for Ion Channel Research
2026-09-17
Build reproducible Tetrandrine experiments for calcium signaling, inflammation, and cancer biology research. This workflow combines solvent-aware dosing, orthogonal readouts, and structure-based screening logic without overstating evidence for unvalidated targets.
-
Streptavidin-Cy3 for Mechanistic Cancer Assays
2026-09-17
Streptavidin-Cy3 connects biotin-based fluorescence with spatially resolved cancer biology. This guide translates a nasopharyngeal carcinoma super-enhancer study into practical ISH, IHC, immunofluorescence, and flow cytometry assay decisions while defining important evidence limits.
-
Z-VAD-FMK: A Functional Test for Cell Death
2026-09-16
Z-VAD-FMK is more than a pan-caspase inhibitor: it is a causal tool for distinguishing apoptosis from caspase-independent death. This article uses the honokiol-induced paraptosis-like death study in NB4 cells to develop a practical assay framework for apoptosis inhibition, caspase activity measurement, and cancer research.
-
Sulforaphane, ROS, and NLRP3 in Ulcerative Colitis
2026-09-15
A 2024 study in Biomedicine & Pharmacotherapy found that Sulforaphane reduced disease features in dextran sodium sulfate-induced colitis and suppressed oxidative stress-linked NLRP3 inflammasome activation. Its main contribution is the combination of mouse and macrophage experiments, although the findings remain preclinical and do not establish clinical efficacy or direct NLRP3 binding.
-
NMDA–Cav2.1 Control of PV Interneuron Maturation
2026-09-15
Singh et al. show that developmental NMDAR signaling in prospective parvalbumin interneurons is required for maturation of Cav2.1-dependent GABA release, rather than merely for maintaining interneuron excitability. The work links Grin1 loss to impaired inhibitory output and provides a mechanistic framework for understanding how altered fast-spiking interneuron development may affect cortical excitation–inhibition balance.
-
CD47 Blocks Phagocytosis Through Vav Dephosphorylation
2026-09-14
Miller et al. identify Vav dephosphorylation as a critical downstream event by which CD47 suppresses macrophage phagocytosis. Live-cell imaging and mechanistic perturbations show that CD47 selectively restrains Rac-dependent reaching while leaving a less frequent Rho-dependent sinking pathway available, clarifying an important checkpoint for antibody-mediated clearance and cancer immunotherapy research.
-
CHK1 Inhibition in Breast Cancer: ER/PR-Dependent Effects
2026-09-14
The reference study shows that CHK1 inhibition produces distinct outcomes according to estrogen-receptor and progesterone-receptor status. Its integrated database, functional, and transcriptomic analyses explain why CHK1 blockade sensitizes ER−/PR−/HER2− models to adriamycin but has mainly single-agent activity in ER+/PR+/HER2− models.
-
Butylated Hydroxyanisole (BHA) for Redox Precision
2026-09-13
Butylhydroxyanisole (BHA) is more useful to translational researchers when treated as a controlled redox perturbation rather than a generic antioxidant. This thought-leadership guide connects its free-radical chemistry to assay design, ROS interpretation, pathway validation, and the discipline required to translate oxidative stress findings without overstating mechanism.
-
Filipin III: From Cholesterol Signal to Lipid Flux
2026-09-12
Filipin III provides a spatial readout of accessible membrane cholesterol, but its greatest value emerges when imaging is integrated with lipid-flux biology. This article explains how the probe can help interpret SOAT1-driven cholesterol remodeling in PHMG-induced pulmonary fibrosis while avoiding common assay overinterpretations.
-
SB525334: TGF-beta1 Receptor Inhibitor Workflows
2026-09-12
SB525334 offers a selective way to test whether ALK5-driven TGF-beta signaling controls fibrosis, renal injury, or wound-repair phenotypes. This practical workflow connects acute Smad2/3 phosphorylation inhibition with longer-term matrix, angiogenic, and immune readouts inspired by diabetic foot ulcer research.
-
L-NAME Hydrochloride: A Pathway Deconvolution Guide
2026-09-11
L-NAME Hydrochloride, also known as NG-nitro-L-arginine methyl ester, is more than a routine NOS inhibitor. This guide shows how to use it as a mechanistic control for separating nitric oxide signaling from prostaglandin- and receptor-mediated vascular responses.